Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04729985 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Diabetes Discharge Transitional CGM Study (DDT-CGM)

Study acronym: DDT-CGM
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 26, 2024 (before its estimated July 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 1, 2023 to Jul 1, 2024
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Study completion date: Aug 1, 2023 to Dec 1, 2024
    v4
  2. Primary completion date: Jun 1, 2022 to Apr 1, 2023
    • Study completion date: Sep 1, 2022 to Aug 1, 2023
    v3
  3. Trial status: Not Yet Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
    • Start date changed from estimate of Feb 2021 to Jun 1, 2021
    • Study sites: 0 to 1
    • Primary completion date: Feb 2022 to Jun 1, 2022
    • Study completion date: Apr 2022 to Sep 1, 2022
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Intervention group will receive brief diabetic education, CGM education and use and have a CGM placed before discharge. They will also sign up for "Cloud" access of their CGM data. A medical assistant will review their CGM data daily to make sure they are using the CGM adequately. The principal investigator will review the CGM data and call the patient for a brief phone evaluation of their glucoses and their transition from the hospital to outpatient care. The will be called 4 times between discharge and day 15 by the principal investigator. Standard treatment group will receive a blinded CGM to be reviewed 30 days after discharge. Reduction in hospitalizations and ER visits within the first 30 days is the primary outcome. Time in range, hypoglycemia, hyperglycemia and patient satisfaction will also be evaluated 30 days after discharge.
Trial Details
NCT Number NCT04729985
Lead Sponsor Intermountain Health Care, Inc.
Collaborators: Abbott
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov